<DOC>
	<DOC>NCT00353496</DOC>
	<brief_summary>The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.</brief_summary>
	<brief_title>Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Adenoma, Islet Cell</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Endocrine tumour in the intestine or pancreas and with locally advanced or metastatic disease No hormone related symptoms Well or moderately differentiated tumour confirmed by histology Tumour lesions which are measurable by a CT or MRI scan Previously treated with a somatostatin analogue unless more than 6 months ago and given for no more than 15 days Treated within the last 6 months with interferon, chemoembolisation or chemotherapy or at any time with a radionuclide Had a previous cancer except basal cell carcinoma and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for 5 years Pregnant or lactating Females must use adequate contraception during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Non functioning entero-pancreatic tumours</keyword>
</DOC>